Abstract
The Acute Hepatic Failure Study Group (AHFSG) has conducted a double-blinded, randomized evaluation of hydrocortisone in patients with acute hepatic failure. From July 1975 through August 1978, a 38-month period, 18 medical centers in the United States and one in Canada participated in this trial. A total of 64 patients were accessed and found eligible to participate in the study; two of them were subsequently eliminated from our analysis. Eighteen patients received placebo; 23 received 400 mg hydrocortisone per day, and 21 patients were administered 800 mg hydrocortisone per day. We did not observe any therapeutic effect of hydrocortisone, and the survival rates for placebo versus 400 mg and versus 800 mg hydrocortisone per day were 22%, 9%, and 24%, respectively. Fulminant hepatitis associated with drug hepatotoxicity or non-A, non-B hepatitis seemed to have a worse prognosis than fulminant B, although these differences were not significant. Serum α-fetoprotein had a modest prognostic value of survival and seemed to be limited to fulminant B. The AHFSG recommends, therefore, that corticosteroid use in acute hepatic failure with hepatic encephalopathy be discontinued.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ducci H, Motlis J: Hepatitis fulminante, recuperacion. Rev Med Chile 79:590–594, 1951
Evans AS, Spring H, Nelson RS: Adrenal hormone therapy in viral hepatitis III. The effect of ACTH and cortisone in severe and fulminant cases. Ann Intern Med 38:1148–1159, 1953
Katz R, Velasco M, Klinger J, Alessandri H: Corticosteroids in the treatment of acute hepatitis in coma. Gastroenterology 42:258–265, 1962
Redeker AG, Schweitzer IL, Yamahiro HS: Randomization of corticosteroid therapy in fulminant hepatitis. N Engl J Med 294:728–739, 1976 (letter)
Randomized trial of steroid therapy in acute liver failure: a report from the European Association for the Study of the Liver. Gut 20:620–623, 1979
Acute Hepatic Failure Study Group: Failure of specific immunotherapy in fulminant type B hepatitis. Ann Intern Med 86:272–277, 1977
Trey C, Davidson CJ: The management of fulminant hepatic failure.In Progress in Liver Diseases, Vol. 3 H Popper, F Schaffner (eds). New York, Grune and Stratton, 1970, pp 282–298
Govindarajan S, Chin KP, Redeker AG, Peters RL: Fulminant B viral hepatitis: Role of delta agent. Gastroenterology 86:1417–1420, 1984
De Cock KM, Govindarajan S, Valinluck B, Redeker AG: Hepatitis B virus DNA in fulminant hepatitis B. Ann Intern Med 105:546–547, 1986
Alpert E, Feller ER: Alphafetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis. Gastroenterology 74:856–858, 1978
Mathiesen JR, Skinoj P, Nielsen JO, Purcell RH, Wong D, Ranek L: Hepatitis A, B, and non-A, non-B in fulminant hepatitis. Gut 21:72–77, 1980
Gimson AES, White YS, Eddleston ALWF, Williams R: Clinical prognostic differences in fulminant hepatitis type A, B, and non-A, non-B. Gut 24:1194–1198, 1983
Rakela J, Lange SM, Ludwig J, Baldus WP: Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc 60:289–292, 1985
Ware AJ, Jones RE, Thorey JW, Combes B: A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol 62:130–133, 1974
Davis GL, Hoofnagle JH: Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med 102:762–765, 1985
Karvountzis GG, Redeker AG: Relation of alphafetoprotein in acute hepatitis to severity and prognosis. Ann Intern Med 80:156–160, 1974
Murray-Lyon IM, Orr AH, Gazzard B, Kohn J, Williams R: Prognostic value of serum alphafetoprotein in fulminant hepatic failure including patients treated by charcoal hemoperfusion. Gut 17:576–580, 1976
Pelemann RR, Gavaler JS, Van Thiel DH, Esquivel C, Gordon R, Iwatsuki S, Starzl TS: Orthotopic liver transplantation for acute and subacute hepatitis failure in adults. Hepatology 7:484–489, 1987
Rakela J, Perkins JD, Gross JB, Jr, Hayes DH, Plevak DJ, Krom RAF, Ludwig J: Acute hepatic failure: The emerging role of orthotopic liver transplantation. Mayo Clin Proc 64:424–428, 1989
Edmond JC, Aran PP, Withington P, Brolsch CE, Baker AL: Liver transplantation in the management of fulminant hepatic failure. Gastroenterology 96:1583–1588, 1989
Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee W-S, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M: An assay for circulating antibodies to a major etiology virus of human non-A, non-B hepatitis. Science 244:362–364, 1989
Alter JH, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321:1494–1500, 1989
Weiner AJ, Kuo G, Bradley DN, Bonino F, Saracco G, Lee C, Rosenblatt J, Choo QL, Houghton M: Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1:1–3, 1990
Author information
Authors and Affiliations
Consortia
Additional information
Supported in part by grants from the National Institute of Health (HL-23420 and CA-30209)
Rights and permissions
About this article
Cite this article
Rakela, J., Mosley, J.W., Edwards, V.M. et al. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. Digest Dis Sci 36, 1223–1228 (1991). https://doi.org/10.1007/BF01307513
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01307513